Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

Core Insights - Nutriband Inc. has signed a non-binding Letter of Intent (LOI) with Qvanta Group to explore collaboration in areas related to quantum-AI technologies and abuse-deterrent pharmaceutical products [1][8] Group 1: Company Overview - Nutriband Inc. specializes in developing transdermal pharmaceutical products, particularly focusing on abuse-deterrent technologies [10] - The company's lead product is an abuse-deterrent fentanyl transdermal system, supported by a comprehensive intellectual property portfolio with patents granted in multiple countries [9] Group 2: Collaboration with Qvanta - Qvanta Group, which includes Qvanta LLC and its subsidiaries, is focused on advanced technology development, particularly in quantum-AI cybersecurity and computing platforms [2] - The LOI aims to explore potential collaboration in secure AI and analytics platforms for pharmaceutical data, cybersecurity frameworks, and advanced modeling capabilities [7] Group 3: Federal Priorities - The collaboration aligns with federal priorities, including the designation of illicit fentanyl as a Weapon of Mass Destruction, emphasizing its threat to national security [3] - The U.S. Administration's AI Action Plan aims to accelerate the responsible adoption of AI in regulated sectors, including healthcare and pharmaceuticals [4] - The Genesis Mission Executive Order highlights the strategic importance of quantum information science in addressing national challenges [5]